Merck acquires ThemisMerck’s acquisition of Themis is expected to accelerate the development of a measles vector-based SARS-CoV-2 vaccine candidate. Sanofi, GSK collaborate to develop COVID-19 vaccineSanofi and GSK aim to complete the development required for availability of a COVID-19 vaccine by the second half of 2021. Merck gets FDA green light for Ervebo Merck's Ervebo is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years old and older. First Previous 35 36 37
